Pular para o conteúdo
Merck
Todas as fotos(1)

Key Documents

SML3194

Sigma-Aldrich

ZSTK474

≥98% (HPLC)

Sinônimo(s):

2-(2-Difluoromethylbenzimidazol-1-yl)-4,6-dimorpholino-1,3,5-triazine, 2-(Difluoromethyl)-1-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)-1H-benzimidazole, 4,4′-(6-(2-(Difluoromethyl)-1H-benzo[d]imidazol-1-yl)-1,3,5-triazine-2,4-diyl)dimorpholine, ZSTK 474, ZSTK-474, 2-(2-Difluoromethylbenzoimidazol-1-yl)-4, 6-dimorpholino-1, 3, 5-triazine

Faça loginpara ver os preços organizacionais e de contrato

Selecione um tamanho


Selecione um tamanho

Alterar visualização

About This Item

Fórmula empírica (Notação de Hill):
C19H21F2N7O2
Número CAS:
Peso molecular:
417.41
Código UNSPSC:
12352200
NACRES:
NA.77

Nível de qualidade

Ensaio

≥98% (HPLC)

forma

powder

cor

white to beige

solubilidade

DMSO: 2 mg/mL, clear (warmed)

temperatura de armazenamento

−20°C

InChI

1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2

chave InChI

HGVNLRPZOWWDKD-UHFFFAOYSA-N

Procurando produtos similares? Visita Guia de comparação de produtos

Ações bioquímicas/fisiológicas

A novel s-triazine derivative, ZSTK474 [2-(2-difluoromethylbenzimidazol-1-yl)-4,6-dimorpholino-1,3,5-triazine], strongly inhibited the growth of tumor cells. A molecular target for ZSTK474 is PI3K. ZSTK474 directly inhibits PI3K activity more efficiently than the PI3K inhibitor LY294002. At concentrations of 1μM, ZSTK474 and LY2194002 reduced PI3K activity to 4.7% (95% confidence interval [CI] = 3.2% to 6.1%) and 44.6% (95% CI = 38.9% to 50.3%), respectively, of the untreated control level. Molecular modeling of the PI3K-ZSTK474 complex indicated that ZSTK474 could bind to the ATP-binding pocket of PI3K. ZSTK474 inhibited phosphorylation of signaling components downstream from PI3K, such as Akt and glycogen synthase kinase 3β, and mediated a decrease in cyclin D1 levels. ZSTK474 administered orally to mice had strong antitumor activity against human cancer xenografts without toxic effects in critical organs. Akt phosphorylation was reduced in xenograft tumors after oral administration of ZSTK474. ZSTK474 is a new PI3K inhibitor with strong antitumor activity against human cancer xenografts without toxic effects in critical organs.
ZSTK474 is an orally active, potent and selective, ATP-competitive inhibitor against class I phosphatidylinositol 3 kinase isoforms (PI3K IC50 in nM = 4.6/δ, 16/α, 44/β, 49/γ with = 10 μM ATP; mTOR IC50 >100 μM) with 27-fold selectivity for PI3Kα over DNA-PK. ZSTK474 inhibits PI3K-mediated signaling events in A549 cells in cultures (0.5 μM; Akt pSer473, GSK-3β pSer9, cyclinD1 expression) and induces tumor growth arrest or regression in mice in vivo (100, 200, or 400 mg/kg via daily p.o. against murine B16F10 melanoma or human A549 lung cancer, PC-3 prostate cancer, and WiDr colon cancer).

Implicações do diagnóstico

Potent antitumor activity by oral administration against murine solid tumors and human cancer xenografts

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable


Certificados de análise (COA)

Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica